NCT00299702View on ClinicalTrials.gov

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL

Enrollment

355

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

SchizophreniaPsychotic Disorders

Interventions

DRUG

Abilify

10-30 mg once daily for 104 weeks

DRUG

Risperidal Consta

25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks

All Listed Sponsors

collaborator

Janssen, LP

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00299702 - Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter